Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 23Carcinoma, Non-Small-Cell Lung 12Colorectal Neoplasms 8Biliary Tract Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Mesothelioma, Malignant 5Melanoma 5Liver Neoplasms 5Cholangiocarcinoma 5Urinary Bladder Neoplasms 4Prostatic Neoplasms 4Neoplasms 4Diabetes Mellitus, Insulin-Dependent, 12 4Neoplasm Metastasis 3Lung Neoplasms 3Head and Neck Neoplasms 3Fallopian Tube Neoplasms 3Carcinoma, Renal Cell 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Recurrence 2Ovarian Neoplasms 2Neoplasms, Germ Cell and Embryonal 2Mesothelioma 2Gallbladder Neoplasms 2Endometrial Neoplasms 2Adenocarcinoma Of Esophagus 2Vascular Neoplasms 1Uveal Melanoma 1

Interventions

Cisplatin 66Paclitaxel 43Radiotherapy 39Carboplatin 29Fluorouracil 27Drug Therapy 20Irinotecan 16toripalimab 15pembrolizumab 15tislelizumab 14camrelizumab 13sintilimab 12Radiotherapy, Intensity-Modulated 11Albumin-Bound Paclitaxel 11S 1 (combination) 10Capecitabine 10130-nm albumin-bound paclitaxel 10apatinib 9Radiation 9Oxaliplatin 9Neoadjuvant Therapy 9Esophagectomy 9Docetaxel 9nimotuzumab 8TP protocol 8Cetuximab 8anlotinib 7Nivolumab 7nedaplatin 6Taxes 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Esophageal Squamous Cell Carcinoma × tremelimumab × Clear all
NCT03377400 2020-12-17

Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer

Samsung Medical Center

Phase 2 Unknown
40 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡